CZC-54252 MedChemExpress (MCE)

Product Name	CZC-54252
Synonyms	CS-1730 CZC54252 CZC 54252 CZC-54252 CZC 54252 hydrochloride N-(2-(5-chloro-2-(2-methoxy-4-morpholinophenylamino)pyrimidin-4-ylamino)phenyl)methanesulfonamide Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- Synonyms CS-1730 CZC54252 CZC 54252 CZC-54252 CZC 54252 hydrochloride N-(2-(5-chloro-2-(2-methoxy-4-morpholinophenylamino)pyrimidin-4-ylamino)phenyl)methanesulfonamide Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- N-[2-[[5-Chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]methanesulfonamide hydrochloride
CAS	1191911-27-9
EINECS
Chemical Formula	C22H25ClN6O4S
Molecular Weight	504.99
inchi
Package	10 mM * 1 mL;5 mg;10 mg;50 mg
Price	Email to quote
Descriptions	CZC-54252 CZC-54252 MedChemExpress (MCE) HY-B0792 1191911-27-9 99.38% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US Descriptions CZC-54252 CZC-54252 MedChemExpress (MCE) HY-B0792 1191911-27-9 99.38% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US may vary elsewhere. CZC-54252 is a potent and selective LRRK2 inhibitor with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. CZC-54252 attenuates G2019S LRRK2-induced human neuronal injury with an EC50 of ~1 nM. CZC-54252 has a neuroprotective activity. CZC-54252 inhibits the activity of recombinant human wild-type LRRK2 with an IC50 ranging from ～1 to ～5 nM. In addition, they are screened against a kinase panel of 185 kinases and exhibited good selectivity[1]. G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 with an EC50 of ~1 nM and fully reversed to wild-type levels by CZC-54252 at concentration of 1.6 nM[1]. IC50: 1.28 nM (Wild-type LRRK2) and 1.85 nM (G2019S LRRK2)[1] In Vitro CZC-54252 inhibits the activity of recombinant human wild-type LRRK2 with an IC50 ranging from ～1 to ～5 nM. In addition, they are screened against a kinase panel of 185 kinases and exhibited good selectivity[1]. G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 with an EC50 of ~1 nM and fully reversed to wild-type levels by CZC-54252 at concentration of 1.6 nM[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> CZC-54252 Related Antibodies \| \| \| \| \| \| \| \| \| \| [1]. Ramsden N, et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 2011 Oct 21 6(10):1021-8. [Content Brief]
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-04-01 14:45:47

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-04-01 14:45:47

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-04-01 14:45:47

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-04-01 14:45:47

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-04-01 14:45:47

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-04-01 14:45:47

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-04-01 14:45:47

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact